Tempo reale stimato
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
10,3 USD | -2,69% | -17,75% | -52,18% |
15/04 | NEVRO CORP. : RBC Capital Markets mantiene la raccomandazione Neutral | ZM |
11/04 | NEVRO CORP. : Mizuho Securities conferma il giudizio Neutral | ZM |
Attività
Numero di dipendenti: 1 215
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Medical Devices
100,0
%
| 406 | 100,0 % | 425 | 100,0 % | +4,63% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
86,2
%
| 348 | 85,7 % | 367 | 86,2 % | +5,28% |
International
13,8
%
| 58 | 14,3 % | 59 | 13,8 % | +0,72% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Kevin Thornal
CEO | Chief Executive Officer | 50 | 24/04/23 |
D. Grossman
CHM | Chairman | 63 | 19/03/19 |
Roderick MacLeod
DFI | Director of Finance/CFO | 57 | 15/06/20 |
David Caraway
CTO | Chief Tech/Sci/R&D Officer | 67 | 01/04/14 |
Chief Tech/Sci/R&D Officer | 73 | 20/01/20 | |
Chief Tech/Sci/R&D Officer | 54 | 01/07/16 | |
Geeta Kaveti
CMP | Compliance Officer | - | - |
Kerry Bradley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Michael DeMane
BRD | Director/Board Member | 67 | 17/03/11 |
Angeline McCabe
IRC | Investor Relations Contact | - | - |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Michael DeMane
BRD | Director/Board Member | 67 | 17/03/11 |
Karen Prange
BRD | Director/Board Member | 60 | 17/12/19 |
D. Grossman
CHM | Chairman | 63 | 19/03/19 |
Director/Board Member | 64 | 19/03/19 | |
Kevin O'Boyle
BRD | Director/Board Member | 68 | 19/03/19 |
Frank Fischer
BRD | Director/Board Member | 82 | 01/10/12 |
Susan Siegel
BRD | Director/Board Member | 63 | 02/12/20 |
Shawn McCormick
BRD | Director/Board Member | 59 | 01/09/14 |
Sridhar Kosaraju
BRD | Director/Board Member | 46 | 31/08/21 |
Kevin Thornal
CEO | Chief Executive Officer | 50 | 24/04/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 37 364 308 | 35 498 213 ( 95,01 %) | 682 916 ( 1,828 %) | 95,01 % |
Coordinate società
Settore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-52,18% | 388 Mln | |
-3,17% | 184 Mrd | |
-1,82% | 107 Mrd | |
-4,18% | 67,78 Mrd | |
+0,80% | 50,66 Mrd | |
+12,48% | 47,64 Mrd | |
+4,60% | 41,12 Mrd | |
+1,90% | 26,3 Mrd | |
+2,45% | 26,04 Mrd | |
+15,06% | 25,4 Mrd |
- Borsa valori
- Azioni
- Azione NVRO
- Società Nevro Corp.